- |||||||||| Piqray (alpelisib) / Novartis
Trial completion date, Trial primary completion date, Metastases: BYLieve: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (clinicaltrials.gov) - Jul 9, 2019 P2, N=340, Recruiting, N=59 --> 77 | Completed --> Terminated; Business objectives have changed. Trial completion date: Sep 2020 --> Nov 2021 | Trial primary completion date: Apr 2020 --> Nov 2020
- |||||||||| letrozole / Generic mfg.
Enrollment status, Trial completion date, Trial primary completion date: Intrauterine Insemination With Letrozole Versus in Natural Cycle (clinicaltrials.gov) - Jul 8, 2019 P=N/A, N=100, Recruiting, Trial completion date: Sep 2020 --> Nov 2021 | Trial primary completion date: Apr 2020 --> Nov 2020 Enrolling by invitation --> Recruiting | Trial completion date: May 2019 --> Feb 2020 | Trial primary completion date: Apr 2019 --> Aug 2019
- |||||||||| letrozole / generics
Journal, HEOR: Association between depression, symptom experience and quality of life in polycystic ovary syndrome. (Pubmed Central) - Jul 7, 2019 P3 Disturbances in health-related quality of life in Depressed women are not explained by objective measures including body mass index, hirsutism scores and duration of infertility. Depression may color the experience of polycystic ovary syndrome symptoms and should be considered when there is significant discordance between subjective and objective measures in women with polycystic ovary syndrome.
- |||||||||| Evomate (raloxifene hydrochloride) / Shreya Life Sciences
Journal: Combined Raloxifene and Letrozole for Breast Cancer Patients. (Pubmed Central) - Jul 5, 2019 The study indicates that the combination of letrozole and raloxifene possess additive effect in terms of cytotoxicity of cancer cell lines (MCF-7) and negligible effects in normal cell lines (HEK). Our study indicates that the addition of raloxifene doesn't interfere with anticancer efficacy of letrozole rather the combination acted additively for the treatment of breast cancer.
- |||||||||| metformin / generics
Clinical, Review, Journal: A Review of Second- and Third-line Infertility Treatments and Supporting Evidence in Women with Polycystic Ovary Syndrome. (Pubmed Central) - Jun 30, 2019 In clomiphene-citrate-resistant anovulatory women with polycystic ovary syndrome (PCOS) and no other infertility factors, either metformin combined with clomiphene citrate or gonadotrophins could be used as a second-line pharmacological therapy, although gonadotrophins are more effective...The usefulness of letrozole as a second-line pharmacological treatment for ovulation induction in clomiphene-citrate-resistant women with PCOS requires further research...For women with PCOS undergoing IVF/ICSI treatment, the gonadotropin-releasing hormone (GnRH) antagonist protocol is preferred and an elective frozen embryo transfer strategy could be considered. In assisted conception units with sufficient expertise, in-vitro maturation (IVM) of oocytes could be offered to women with PCOS.
- |||||||||| letrozole / generics
Preclinical, Journal: The sex-dependent effects of letrozole on anxiety in middle-aged rats. (Pubmed Central) - Jun 28, 2019 This sex-specific effect might be related to sex differences of estrogen and androgen signaling in aging brains. These results should be taken into account in clinical applications of letrozole, especially in men.
- |||||||||| letrozole / generics
Clinical, Journal: Translation and implementation of the Australian-led PCOS guideline: clinical summary and translation resources from the International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. (Pubmed Central) - Jun 22, 2019 Main recommendations: The recommendations cover the following broad areas: diagnosis, screening and risk assessment depending on life stage; emotional wellbeing; healthy lifestyle; pharmacological treatment for non-fertility indications; and assessment and treatment of infertility. Changes in management as a result of this guideline: •Diagnosis:▪when the combination of hyperandrogenism and ovulatory dysfunction is present, ultrasound examination of the ovaries is not necessary for diagnosis of PCOS in adult women;▪requires the combination of hyperandrogenism and ovulatory dysfunction in young women within 8 years of menarche, with ultrasound examination of the ovaries not recommended, owing to the overlap with normal ovarian physiology; and▪adolescents with some clinical features of PCOS, but without a clear diagnosis, should be regarded as "at risk" and receive follow-up assessment.•Screening for metabolic complications has been refined and incorporates both PCOS status and additional metabolic risk factors.•Treatment of infertility: letrozole is now first line treatment for infertility as it improves live birth rates while reducing multiple pregnancies compared with clomiphene citrate.
- |||||||||| Ibrance (palbociclib) / Pfizer
Toxicity of Radiation Therapy Given Concomitantly with Palbociclib for Metastatic Breast Carcinoma (ASTRO Innovation Hub) - Jun 21, 2019 - Abstract #ASTRO2019ASTRO_532; However, numbers are small and the amount of mucosal toxicity observed may be out of proportion to the expected side effects based on dose alone. Our current policy is to continue palbociclib during RT for palliative treatment of metastatic ER-positive, Her2-negative breast carcinoma but monitor patients closely when treating mucosal sites or adjacent structures.
- |||||||||| Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche
Trial completion date, Trial primary completion date: PALTAN: Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (clinicaltrials.gov) - Jun 19, 2019 P2, N=48, Recruiting, Our current policy is to continue palbociclib during RT for palliative treatment of metastatic ER-positive, Her2-negative breast carcinoma but monitor patients closely when treating mucosal sites or adjacent structures. Trial completion date: Nov 2024 --> Jul 2020 | Trial primary completion date: Nov 2019 --> May 2020
- |||||||||| Arimidex (anastrozole) / AstraZeneca, Remedica
Journal: Aromatisation of steroids in the bivalve Mytilus trossulus. (Pubmed Central) - Jun 16, 2019 Enzymatic complex (aromatase-like enzyme) catalysing aromatisation in mussels was found to be insensitive to inhibitory effect of selective inhibitors of mammalian aromatase such as letrozole and anastrazole, suggesting its different structure from vertebrate aromatase. Further in vivo studies using C-labeled steroids at 8 °C temperature window confirmed that bivalves are able to uptake testosterone and androstenedione from the ambient environment and metabolise them to estrone and 17β-estradiol thus confirming endogenous estrogen' synthesis.
- |||||||||| Tamoxis (tamoxifen) / Bioprofarma
Journal: Treatment of Girls and Boys with McCune-Albright Syndrome with Precocious Puberty - Update 2017. (Pubmed Central) - Jun 15, 2019 This article will also review the current treatment strategies in boys which typically include using an androgen receptor blocker and an aromatase inhibitor. Due to the rarity of the condition, large multicenter collaborative studies are needed to further investigate efficacy and safety with the goal of establishing the gold standard for treatment of PP in children with MAS.
- |||||||||| Esmya (ulipristal acetate) / ASKA, HRA Pharma, Allergan, Gedeon Richter
Journal: Resistance of primary breast cancer cells with enhanced pluripotency and stem cell activity to sex hormonal stimulation and suppression. (Pubmed Central) - Jun 15, 2019 Isolation and characterization of patient-derived breast cancer stem cells in large clinical studies is therefore crucial to identify new targets for endocrine therapies, potentially directed towards stemness and pluripotency markers. Such direction may help overcoming endocrine resistance and draw attention to breast cancer stem cells' behaviour under endogenous and exogenous sex hormones throughout a woman's reproductive life.
- |||||||||| Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Jun 14, 2019 P1, N=256, Active, not recruiting, Such direction may help overcoming endocrine resistance and draw attention to breast cancer stem cells' behaviour under endogenous and exogenous sex hormones throughout a woman's reproductive life. Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Nov 2019 --> Nov 2020
- |||||||||| letrozole / generics, cyclophosphamide oral / generics
Journal: Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR. (Pubmed Central) - Jun 9, 2019 Furthermore, levels of the apoptosis-related marker, M30, decreased in responders of endocrine therapy, suggesting that the induction of apoptosis by metronomic chemoendocrine therapy was involved in the improved clinical outcome compared with endocrine therapy. In conclusion, metronomic chemoendocrine therapy induced a different cellular reaction from that of endocrine therapy, including the induction of apoptosis, which is likely to contribute to improved efficacy compared with endocrine therapy alone.
|